Interplay Between Cancer Cell Cycle and Metabolism: Challenges, Targets and Therapeutic Opportunities
Overview
General Medicine
Pharmacology
Authors
Affiliations
A growing interest has emerged in the field of studying the cross-talk between cancer cell cycle and metabolism. In this review, we aimed to present how metabolism and cell cycle are correlated and how cancer cells get energy to drive cell cycle. Cell proliferation and cell death largely depend on the metabolic activity of the cell. Cell cycle proteins, e.g. cyclin D, cyclin dependent kinase (CDK), some pro-apoptotic and anti-apoptotic proteins, and P53 have been shown to be regulated by metabolic crosstalk. Dysregulation of this cross-talk between metabolism and cell cycle leads to degenerative disorder(s) and cancer. It is not fully understood the actual reason of aberration between metabolism and cell cycle, but it is a hallmark of cancer research. Herein, we discussed the role of some regulatory molecules relative of cell cycle and metabolism and highlight how they control the function of each other. We also pointed out, current therapeutic opportunities and some additional crucial therapeutic targets on these fields that could be a breakthrough in cancer research.
Insights into Metabolic Reprogramming in Tumor Evolution and Therapy.
Chiu C, Guerrero J, Regalado R, Zamora M, Zhou J, Notarte K Cancers (Basel). 2024; 16(20).
PMID: 39456607 PMC: 11506062. DOI: 10.3390/cancers16203513.
Zhao H, Cheng X, Yan L, Mi F, Wang W, Hu Y Cell Commun Signal. 2024; 22(1):283.
PMID: 38783346 PMC: 11112774. DOI: 10.1186/s12964-024-01657-z.
Potential role of lncRNA LOXL1-AS1 in human cancer development: a narrative review.
Tang M, Rong Y, Liu S, Wu Z, Ma G, Li X Transl Cancer Res. 2024; 13(4):1997-2011.
PMID: 38737681 PMC: 11082674. DOI: 10.21037/tcr-23-1450.
Size-Specific Modulation of a Multienzyme Glucosome Assembly during the Cell Cycle.
Jeon M, Schmitt D, Kyoung M, An S ACS Bio Med Chem Au. 2023; 3(5):461-470.
PMID: 37876499 PMC: 10591302. DOI: 10.1021/acsbiomedchemau.3c00037.
Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems.
Kang X, Jadhav S, Annaji M, Huang C, Amin R, Shen J Pharmaceutics. 2023; 15(6).
PMID: 37376016 PMC: 10302862. DOI: 10.3390/pharmaceutics15061567.